Orlando Gonzalez Morales, MD
Surgery · Manati, PRNPI 1255334744
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,180 of the $5,885 with a category attached, or 71.0%. KCI USA, Inc. accounts for 82.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $4,751 and has fallen 95.0% since, to $239 in 2025.
Across 28 payments — averaging $210.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- KCI USA, Inc.$5K
- Smith+Nephew$295
- Edwards Lifesciences$237
- Johnson And Johnson International$222
- Medline Industries LP$109
- Johnson & Johnson$83
- plus $73 from 1 others
What the payments were for
- Consulting fees$4508%
- Speaking & faculty fees$4,18071%
- Travel & lodging$220%
- Food & beverage$1,23221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| KCI USA, Inc. | 11 | $4,865 |
| Smith+Nephew | 4 | $295 |
| Edwards Lifesciences | 3 | $237 |
| Johnson And Johnson International | 4 | $222 |
| Medline Industries LP | 1 | $109 |
| Johnson & Johnson | 4 | $83 |
| Solventum Corporation | 1 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PREVENA$3,080
- ABTHERA$2,640
- VAC ULTA$1,540
- V.A.C. VERAFLO$450
- Iodosorb Ointment 40g USA$137
- PICO Single Use Negative Pressure Wound Therapy$131
- Acticoat Range$131
- MEDLINE INDUSTRIES, INC.$109
- ClearSight System$103
How this compares
$5,885 in reported general payments places this provider in the 80th percentile of 202 surgery providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 13 | $12,673 |
| Cefadroxil | 80 | $630 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 42 | $523 |
| Levofloxacin | 25 | $234 |
| Gabapentin | 12 | $194 |
| Clindamycin Hcl | 13 | $163 |
Paid to pharmacies, not to this prescriber.
Other surgery in Manati
- Luis BonillaManati$5K
- Jean Riviere WilliamManati$2K
- Luis GuaspMayaguez$148K
- Fernando Rivera CruzSan Juan$88K
- Laura Rodriguez RiveraPonce$73K
- Jorge Pelet MejiasSan Juan$50K
- Miguel Baez StellaBayamon$48K
- Jose PaganFajardo$39K
- Ariel BermudezBayamon$18K
- Emilio Perez de LeonBayamon$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.